Analysts Set Bioventus Inc. (NASDAQ:BVS) Target Price at $14.75

Shares of Bioventus Inc. (NASDAQ:BVS) have been assigned a consensus rating of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $14.75.

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Bioventus in a research report on Tuesday, June 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. Barrington Research reissued an “outperform” rating and set a $14.00 price objective on shares of Bioventus in a research note on Tuesday, June 30th. Finally, CJS Securities started coverage on shares of Bioventus in a report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price objective on the stock.

Bioventus Price Performance

Shares of BVS stock opened at $12.06 on Wednesday. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of 29.41, a PEG ratio of 1.58 and a beta of 0.65. The business’s fifty day moving average is $9.88 and its 200 day moving average is $9.14. Bioventus has a twelve month low of $5.81 and a twelve month high of $12.53. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The business had revenue of $132.09 million during the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Research analysts expect that Bioventus will post 0.79 EPS for the current fiscal year.

Institutional Trading of Bioventus

A number of hedge funds have recently made changes to their positions in the stock. Hillsdale Investment Management Inc. raised its stake in Bioventus by 148.7% during the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after buying an additional 401,230 shares during the last quarter. Wesbanco Bank Inc. purchased a new stake in shares of Bioventus in the first quarter worth $895,000. Legato Capital Management LLC grew its stake in shares of Bioventus by 1,042.8% in the fourth quarter. Legato Capital Management LLC now owns 137,562 shares of the company’s stock worth $1,023,000 after acquiring an additional 125,525 shares during the last quarter. Inspire Investing LLC bought a new position in shares of Bioventus during the first quarter valued at $1,670,000. Finally, Anderson Financial Strategies LLC increased its holdings in shares of Bioventus by 58.3% during the fourth quarter. Anderson Financial Strategies LLC now owns 213,208 shares of the company’s stock valued at $1,586,000 after acquiring an additional 78,488 shares in the last quarter. 62.94% of the stock is owned by institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.